GLP-1/GIP Agonists in PsA

Improving disease activity among overweight/obese patients with PsA 

(Now recruiting)

Type

Observational

Purpose

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with substantial fatigue, pain, joint stiffness, and diminished function. Obesity is strongly associated with an increased risk of developing psoriasis and psoriatic arthritis and with higher levels of both skin and joint disease activity. However, little is known about the mechanisms linking these conditions.

The purpose of the study is to learn about different treatments for weight loss and how they impact disease activity in psoriatic arthritis (PsA).

Eligibility

You may be eligible for this study if you:

• Are aged >18;
• Have been diagnosed with psoriatic arthritis and currently have some disease activity; and
• Have been prescribed semaglutide or tirzepatide and are ready to start treatment.

Participation

Participants who have been prescribed semaglutide or tirzepatide by another healthcare provider will also be followed by the rheumatology clinic for 24 weeks to assess changes in psoriatic disease activity.

You will be followed over the course of 24 weeks, with full skin and joint examinations, blood work, and questionnaires at Baseline, 3 Months, and 6 Months.